

Two variants on T2DM susceptible gene HHEX are associated with CRC risk in a Chinese population

Rui Sun^{1,*}, Jian-Ping Liu^{1,*}, Chang Gao¹, Ying-Ying Xiong², Min Li¹, Ya-Ping Wang¹, Yan-Wei Su¹, Mei Lin³, An-Li Jiang¹, Ling-Fan Xiong¹, Yan Xie⁴, Jue-Ping Feng¹

¹Department of Oncology, PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

²Department of Clinical Laboratory, PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

³Department of Endocrinology, Wuhan PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

⁴Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America

*These authors have contributed equally to this work

Correspondence to: Jue-Ping Feng, email: fengjuepingpuai@163.com

Keywords: type 2 diabetes mellitus, HHEX, colorectal cancer, genetic variants

Received: November 07, 2015

Accepted: March 28, 2016

Published: April 20, 2016

ABSTRACT

Increasing amounts of evidence has demonstrated that T2DM (Type 2 Diabetes Mellitus) patients have increased susceptibility to CRC (colorectal cancer). As HHEX is a recognized susceptibility gene in T2DM, this work was focused on two SNPs in HHEX, rs1111875 and rs7923837, to study their association with CRC. T2DM patients without CRC (T2DM-only, n=300), T2DM with CRC (T2DM/CRC, n=135), cancer-free controls (Control, n=570), and CRC without T2DM (CRC-only, n=642) cases were enrolled. DNA samples were extracted from the peripheral blood leukocytes of the patients and sequenced by direct sequencing. The χ^2 test was used to compare categorical data. We found that in T2DM patients, rs1111875 but not the rs7923837 in HHEX gene was associated with the occurrence of CRC ($p=0.006$). For rs1111875, TC/CC patients had an increased risk of CRC ($p=0.019$, OR=1.592, 95%CI=1.046-2.423). Moreover, our results also indicated that the two variants of HHEX gene could be risk factors for CRC in general population, independent on T2DM ($p<0.001$ for rs1111875, $p=0.001$ for rs7923837). For rs1111875, increased risk of CRC was observed in TC or TC/CC than CC individuals ($p<0.001$, OR= 1.780, 95%CI= 1.385-2.287; $p<0.001$, OR= 1.695, 95%CI= 1.335-2.152). For rs7923837, increased CRC risk was observed in AG, GG, and AG/GG than AA individuals ($p<0.001$, OR= 1.520, 95%CI= 1.200-1.924; $p=0.036$, OR= 1.739, 95%CI= 0.989-3.058; $p<0.001$, OR= 1.540, 95%CI= 1.225-1.936). This finding highlights the potentially functional alteration with HHEX rs1111875 and rs7923837 polymorphisms may increase CRC susceptibility. Risk effects and the functional impact of these polymorphisms need further validation.

INTRODUCTION

Accumulated evidence has demonstrated that diabetes is a risk factor of various types of cancers such as colorectum (RR=1.3) [1], breast (RR=1.2) [2], endometrium (RR=2.1) [3], bladder (RR=1.35) [4], liver (RR=2.5) [5], and pancreas (RR=1.94) [6] cancer. Cancer patients with DM have a poorer prognosis than those without DM [7–9]. Type 2 diabetes mellitus

(T2DM) have threaten more than 200 million individuals worldwide and its prevalence continues to increasing in many countries including China. Although the precise mechanisms underlying the development and progression of T2DM have not been elucidated, hereditary factors have been known to contribute to the T2DM. The first-degree relatives of T2DM patients have ~3.5 times the risk of T2DM compared to individuals in the general population [10, 11]. Besides obesity, high red meat

consumption, cigarette smoking and alcohol abuse [12–15], diabetes was involved to hold responsible for the increased cancer incidence and worse prognosis of CRC [16–19]. Nevertheless whether hereditary factors of T2DM contribute to the risk of colorectal cancer is still unknown. It is also unclear whether those factors worsen the prognosis of T2DM.

The gene encoding hematopoietically expressed homeobox (HHEX) has been identified to be related to T2DM [20–25]. HHEX gene encodes a transcription factor involved in Wnt signal pathway fundamental for cell growth and differentiation [26–28]. Aberrant activation of Wnt/ β -catenin signaling promotes the occurrence of colorectal cancer. Deregulation in Wnt/ β -catenin-Tcf/Lef axis [29–34] is responsible for most CRCs [35–37]. Recently, converging interest in unraveling HHEX on the development of hyperglycemia has triggered hundreds of association studies. Polymorphisms of rs1111875 T>C and rs7923837 A>G in HHEX gene have been identified and evaluated. Moreover significant association of rs1111875 or/and rs7923837 with T2DM was observed in many studies [38–42].

Although the association between HHEX polymorphisms and T2DM has been well studied, the association of HHEX SNPs with CRC remains unclear. Therefore, the present study focuses on the association between HHEX polymorphisms and CRC risks in Chinese patients.

RESULTS

CRC risk was higher in T2DM patients than non-T2DM control

T2DM has been identified to be associated with increased risk for CRC [44, 45]. Similar to the previous reported research, we found that the CRC risk in T2DM patients was about 1.3 times higher than that in non-DM control ($p=0.00282$, $OR=1.3097$, $95\%CI=1.097-1.564$), Table 1.

In T2DM patients, rs1111875 variants of HHEX were associated with the occurrence of CRC

Many studies have proved that T2DM was an independent risk factor of CRC [44–48], but the association between HHEX variants and the CRC were rarely studied. In this study, rs1111875 and rs7923837 variants of HHEX were analyzed (Table 2). Both passed the Hardy-Weinberg equilibrium exact test ($P > 0.05$) in selected samples. MAFs were similar to data of Han Chinese in Beijing (CHB) and populations from HapMap (<http://hapmap.ncbi.nlm.nih.gov/>). The detailed genotype and allele distributions of the rs1111875 and rs7923837 in the T2DM-only and T2DM/CRC patients are presented in Table 3.

The frequency of the selected characteristics in 300 cases of T2DM-only and 135 T2DM/CRC patients was shown in Table S1. No significant differences regarding to age ($p=0.71$), gender ($p=0.14$), BMI ($p=0.06$), hypertension ($p=0.26$), smoking status ($p=0.73$), were observed among the T2DM-only and T2DM/CRC. However, there were more drinkers in the T2DM/CRC than in the T2DM-only ($p=0.006$). Since insulin and degree of glycemic control have been considered as risk factors in CRC development and progression [49], fasting serum glucose (FSG), insulin and glycated hemoglobin (HbA1c) were all involved in analysis. No significant differences regarding to these three factors between the two groups were observed. In the total 300 cases of T2DM-only and 135 T2DM/CRC patients, 21 cases of T2DM-only and 6 cases of T2DM/CRC patients were sequencing failure for rs1111875 because of the weak signal or no signal, the sequencing for rs7923837 was all successful. Significant difference in genotype of rs1111875 was observed between the T2DM-only and T2DM/CRC patients ($p=0.006$). We found that the rs1111875 of HHEX was significantly associated with CRC risk. Compared to individuals with TT, those subjects with TC/CC had a significant increased CRC risk ($p=0.019$, $OR=1.592$, $95\%CI=1.046-2.423$), the subjects with CC had a significant increased CRC risk ($p=0.0015$, $OR=2.700$, $95\%CI=1.454-5.014$). Significant difference in allele frequency distribution was observed between T2DM-only and T2DM/CRC ($p < 0.001$, $OR=1.888$, $95\%CI=1.370-2.602$).

Another SNP (rs7923837) was not associated with CRC risk in T2DM patients ($p=0.255$). No significant difference in allele frequency distribution was observed between T2DM-only and T2DM/CRC ($p=0.129$). Taken together, these results indicate that rs1111875 but not rs7923837 in HHEX gene was associated with the occurrence of CRC in T2DM patients. Nonetheless, further questions of whether rs1111875 variant in HHEX gene enhance the occurrence of CRC was T2DM dependent or rs1111875 and rs7923837 could increase the CRC risk without the background of T2DM was soon taken into our consideration.

HHEX variants rs1111875 and rs7923837 were CRC risk factors and independent on the occurrence of T2DM

Based on the results above, a research on health control cohort and CRC-only group was conducted.

The frequency distribution of the selected characteristics of 570 cases of control and 642 CRC-only patients were shown in Table S2. No significant differences regarding to age ($p=0.08$), BMI ($p=0.29$), gender ($p=0.09$), hypertension ($p=0.09$) and drinking status ($p=0.09$) were observed among the control and CRC-only subjects. However, there were more smokers

Table 1: The increased CRC occurrence of T2DM patients

	CRC	non-CRC	p	OR CI (95%)
Non-T2DM	1053	94428	0.00282	1.3097 (1.097-1.564)
T2DM	140	9586		

Table 2: The characteristics of the rs1111875 and rs7923837 in HHEX gene

Polymorphisms	Alleles	MAF	HWE *
rs1111875	T>C	0.288	0.728
rs7923837	A>G	0.228	0.256

*Goodness-of-fit chi-square test was used to assess Hardy–Weinberg equilibrium (HWE) in controls.

Table 3: Association between the rs1111875, rs7923837 of HHEX and risk of CRC in T2DM patients

Polymorphisms	T2DM-only (300)		T2DM/CRC (135)		p	OR (95% CI)
	n	%	n	%		
rs1111875						
TT	162	58.1	60	46.5	0.006	1.00(reference)
TC	91	32.6	43	33.3	0.184 (vs. TT)	1.276 (0.798-2.037) (vs. TT)
CC	26	9.3	26	20.2	0.0015 (vs. TT)	2.700 (1.454-5.014) (vs. TT)
TC/CC	117	41.9	69	53.5	0.019 (vs. TT)	1.592 (1.046-2.423) (vs. TT)
T allele	415		146		<0.001	1.00(reference)
C allele	143		95			1.888 (1.370-2.602)
rs7923837						
AA	174	58.0	87	64.5	0.255	1.00(reference)
AG	111	37.0	45	33.3	0.340 (vs. AA)	1.233 (0.801-1.899) (vs. AA)
GG	15	5.0	3	2.2	0.229 (vs. AA) 0.414 (vs. AG)	2.500 (0.705-8.867) (vs. AA) 2.027 (0.560-7.342) (vs. AG)
AG/GG	126	42.0	48	35.5	0.204	1.312 (0.862-1.998)
A allele	459		219		0.129	1.00(reference)
G allele	141		51			1.319 (0.921-1.888)

Two-sided χ^2 -test for the distributions of either genotype or allele frequencies between the DM-only and DM/CRC crowd. Genotype-specific ORs were adjusted for age, gender, smoking status, drinking status in logistic regression model.

among the CRC-only than among the control (p= 0.04). No significant differences regarding to FSG, insulin and HbA1c was observed between the two groups. In the total 570 cases of control and 642 CRC patients, 33 cases of control and 81 cases of CRC-only patients were

sequencing failure for rs1111875 because of the weak signal or no signal, the sequencing of rs7923837 was all successful. The detailed genotype and allele distributions of the rs1111875 and rs7923837 in the CRC-only patients and health controls were presented in Table 4.

Table 4: Association between the rs1111875, rs7923837 of HHEX and risk of CRC

Polymorphisms	Control(570)		CRC-only(642)		P*	Adjusted OR (95% CI)#
	n	%	n	%		
rs1111875						
TT	304	56.6	244	43.5	<0.001	1.00(reference)
TC	189	35.2	270	48.1	<0.001 (vs TT)	1.780 (1.385-2.287) (vs. TT)
CC	44	8.2	47	8.4	0.125 (vs. TT)	1.331 (0.853-2.075) (vs. TT)
TC/CC	233	43.4	317	56.5	<0.001 (vs. TT)	1.695 (1.335-2.152) (vs. TT)
T allele	797		758		<0.001	1.00(reference)
C allele	277		364			1.382 (1.148-1.663)
rs7923837						
AA	349	61.2	325	50.6	0.001	1.00(reference)
AG	200	35.1	283	44.1	<0.001 (vs. AA)	1.520 (1.200-1.924) (vs. AA)
GG	21	3.7	34	5.3	0.036 (vs. AA)	1.739 (0.989-3.058) (vs. AA)
AG/GG	221	38.8	317	49.4	<0.001 (vs. AA)	1.540 (1.225-1.936) (vs. AA)
A allele	898		959		0.018	1.00(reference)
G allele	242		325			1.258 (1.040-1.520)

* Two-sided χ^2 -test for the distributions of either genotype or allele frequencies between the control and case crowd.

#Genotype-specific ORs were adjusted for age, gender, smoking status, drinking status in logistic regression model.

Significant difference in genotype and allele distributions of both rs1111875 and rs7923837 were observed between the control and CRC-only ($p < 0.001$, $p = 0.001$). For rs1111875, compared with individuals with TT, TC or TC/CC individuals had a significant increased CRC risk ($p < 0.001$, OR= 1.780, 95%CI= 1.385-2.287; $p < 0.001$, OR= 1.695, 95%CI= 1.335-2.152, respectively). For rs7923837, compared with individuals with AA, AG, GG, and AG/GG individuals had a significant increased CRC risk ($p < 0.001$, OR= 1.520, 95%CI= 1.200-1.924; $p = 0.036$, OR= 1.739, 95%CI= 0.989-3.058; $p < 0.001$, OR= 1.540, 95%CI= 1.225-1.936, respectively). Significant difference in allele frequency distribution was observed between the control and CRC-only ($p < 0.001$, $p = 0.018$). These results suggested that the rs1111875 and rs7923837 variant of HHEX gene were the risk factor of CRC, and it was independent on the occurrence of T2DM.

Stratification analyses of rs1111875, rs7923837 and risk of CRC

The effects of rs1111875 or rs7923837 on CRC occurrence were further stratified by age, gender, smoking, drinking status and BMI. As shown in Table 5, the association between HHEX rs1111875 variant and CRC risk appeared stronger in subgroups of age < 55 ($p < 0.001$, OR=1.931, 95%CI =1.375-2.713), non-smokers ($p < 0.001$, OR=1.979, 95%CI =1.416-2.767), drinkers ($P < 0.001$, OR=2.351, 95%CI =1.671-3.309), and BMI < 24 ($P < 0.001$, OR=1.875, 95%CI =1.407-2.497). In both male and female subgroup, the association was significant ($p = 0.022$, OR=1.389, 95%CI=1.020-1.891; $p < 0.001$, OR=2.303, 95%CI=1.574 -3.369, respectively). As shown in Table 6, in both male and female, age ≥ 55 and <55; never or ever smoking, drinking and BMI ≥ 24 and <24 subgroup, the associations were significant.

Table 5: Stratification analyses of rs111875 and risk of CRC

	TT		TC/CC		P*	Adjusted OR (95% CI)#
	Control n (304)	CRC-only n (244)	Control n (233)	CRC-only n (317)		
Gender						
male	166	162	138	187	0.022	1.389 (1.020-1.891)
female	138	82	95	130	<0.001	2.303 (1.574 -3.369)
Age						
≥55	104	142	101	187	0.053	1.356 (0.955 -1.925)
<55	200	102	132	130	<0.001	1.931 (1.375-2.713)
Smoking						
Never	155	121	121	134	0.027	1.419 (1.008-1.997)
Ever	149	123	112	183	<0.001	1.979 (1.416-2.767)
Drinking						
Never	139	121	136	147	0.120	1.242 (0.886-1.740)
Ever	165	123	97	170	<0.001	2.351 (1.671-3.309)
BMI						
≥24	101	76	77	75	0.147	1.294 (0.837-2.001)
<24	203	168	156	242	<0.001	1.875 (1.407-2.497)

*Two-sided χ^2 -test for the distributions of either genotype between the control and CRC-only crowd. #Adjusted for age, gender, smoking status, drinking status in logistic regression model.

Association between the rs111875, rs7923837 polymorphism and the clinicopathological characteristics of CRC patients

The association between the rs111875, rs7923837 polymorphisms and the clinicopathological parameters of CRC patients was presented in Table 7. The differences in rs111875 genotype distribution were statistically significant in stages II vs. IV ($p=0.040$, $OR=1.792$, $95\%CI=0.974-3.296$), and in stages III vs. IV ($p=0.026$, $OR=1.869$, $95\%CI=1.024-3.409$). Similarly, the differences in rs7923837 genotype distributions achieved statistical significance among all stages ($p=0.043$), and in stages II vs. III subgroups ($p=0.004$, $OR=1.628$, $95\%CI=1.143-2.318$). Besides, we also analyzed the association between the rs111875, rs7923837 polymorphisms and the clinicopathological parameters of T2DM/CRC patients (Table S4). It is possible for the small T2DM/CRC sample size, no significant association was observed between different polymorphisms in either rs111875 or rs7923837.

DISCUSSION

The present study investigated the associations between 2 SNPs in HHEX and CRC susceptibility in a Chinese population. We found that that in T2DM patients,

rs111875 but not the rs7923837 variants in HHEX gene could be CRC risk factor. Additionally, our results also indicated that the two variants of HHEX gene could be risk factors for CRC in general population, independent of T2DM.

The mechanisms of increased risk for CRC in T2DM patients have been under extensive study. Both non-hereditary and hereditary factors have been elucidated. Among the non-hereditary mechanism are adipokines [16, 18], mitogenic effect of insulin [17, 19], the tumor-promoting effect of hyperglycemia and hyperinsulinemia in DM status, multiple usage of medication, diabetes-associated comorbidities, tissue-specific inflammation. For hereditary factors, HHEX attracts increasing attention in recent years [50]. Previous GWAS study has indicated that T2DM related variants HHEX rs7923837 could increase cancer risk in patients with diabetes [51].

In this study, we found that the increased CRC risk in T2DM patients compared with non-T2DM patients. Under the background of T2DM, the patients with the polymorphisms of rs111875 T>C are susceptible to CRC than the wide type, which may give a clue about the association of T2DM susceptible SNPs and CRC. Interestingly, apart from the mechanism relying on the basic T2DM, the patients suffer from the HHEX polymorphism of rs111875 T>C and rs7923837A>G are

Table 6: Stratification analyses of rs7923837 and risk of CRC

	AA		AG/GG		P*	Adjusted OR (95% CI)#
	Control n (349)	CRC-only n (325)	Control n (221)	CRC-only n (317)		
Gender						
male	176	219	143	177	0.516	0.994 (0.740-1.338)
female	173	106	78	140	4.610	2.929 (2.028-4.231)
Age						
≥55	201	173	100	145	0.001	1.685 (1.216-2.334)
<55	148	152	121	172	0.030	1.384 (1.001-1.915)
Smoking						
Never	187	151	118	149	0.004	1.564 (1.132-2.160)
Ever	162	174	103	168	0.007	1.519 (1.097-2.103)
Drinking						
Never	209	163	114	138	0.005	1.552 (1.125-2.141)
Ever	140	162	107	169	0.039	1.365 (0.980-1.901)
BMI						
≥24	140	87	85	89	0.007	1.685 (1.130-2.514)
<24	209	238	136	228	0.004	1.472 (1.110-1.952)

*Two-sided χ^2 -test for the distributions of either genotype between the control and CRC-only crowd. #Adjusted for age, gender, smoking status, drinking status in logistic regression model.

Table 7: The association of rs1111875, rs7923837 polymorphisms and clinical stage of CRC patients

Category	rs1111875				rs7923837				
	Clinical stage	TT (244)	TC/CC (317)	p	OR (95% CI)	AA (325)	GA/GG (317)	p	Adjusted OR (95% CI)
I		27	37	0.212	1.00(reference)	31	37	0.043	1.00(reference)
II		93	112	0.382 (vs. I)	0.879 (0.498-1.550) (vs. I)	138	101	0.051 (vs. I)	0.613 (0.356-1.054) (vs. I)
III		110	127	0.323 (vs. I)	0.842 (0.482-1.472) (vs. I)	120	143	0.553 (vs. I)	0.998 (0.584-1.705) (vs. I)
IV		19	41	0.450 (vs. II)	0.959 (0.659-1.395) (vs. II)	36	36	0.004 (vs. II)	1.628 (1.143-2.318) (vs. II)
				0.152 (vs. I)	1.575 (0.754-3.288) (vs. I)			0.362 (vs. I)	0.838 (0.431-1.628) (vs. I)
				0.040 (vs. II)	1.792 (0.974-3.296) (vs. II)			0.153 (vs. II)	1.366 (0.806-2.318) (vs. II)
				0.026 (vs. III)	1.869 (1.024-3.409) (vs. III)			0.299 (vs. III)	0.839 (0.498-1.414) (vs. III)

* Two-sided χ^2 -test for the distributions of either genotype between each stage.

more prone to CRC. Polymorphisms of rs1111875 and rs7923937 are CRC risk factors, which could increase CRC susceptibility independent on the occurrence of T2DM.

Furthermore, we observed that the association between HHEX rs1111875 and increased CRC risk was more prominent in age < 55, non-smokers, drinkers and BMI < 24 subgroup, suggesting that the interaction of age, smoking and drinking status and genetic variants may affect the occurrence of CRC together. Thus, the association of HHEX rs1111875 and CRC occurrence was similar in both male and female subgroup, suggesting that the promotion effect of rs1111875 T>C polymorphism on CRC was not influenced by the gender. The association of HHEX rs7923837 variants and CRC occurrence was similar in both male and female, age \geq 55 and <55; never or ever smoking, drinking and BMI \geq 24 and <24 subgroup, suggesting that the effect of rs1111875 T>C polymorphism on CRC was not affected by the upper factors.

The expression of *HHEX* has been reported to be a fundamental signal for cell growth and development [27]. In line with this, we find significant association between HHEX rs7923837 variants and CRC staging. For rs1111875, the association was significant only between stage II and IV; stage III and IV, we speculate that the influence of rs1111875 is relatively subtle that may slowly promote the development of CRC, but not powerful enough to influence the CRC progression during the early stage of disease.

Since our case-control study was hospital based, we couldn't rule out a possibility of selection bias of these subjects who might be associated with a particular genotype. One of the strengths of this study is that the two-population based association studies between the Polymorphisms of rs1111875 T>C, rs7923837 A>G in HHEX polymorphisms and CRC risk provided sufficient statistical significance and reduce the false-positive report probability. However, several limitations should be addressed. Firstly, the subgroup analysis dealing with interactions between the HHEX genotype are based on the small number of subjects. As studies focused on Chinese are currently limited, further studies on these SNPs including a wider spectrum of subjects should be carried to investigate the role of these variants in different populations by larger prospective studies. Secondly, further functional studies of these two SNPs should be conducted to make a plausible biological explanation for the epidemiologic findings.

In summary, to our knowledge, this study provided the first evidence that the HHEX rs1111875 T>C and rs7923837 A>G may contribute to an increased CRC risk in Chinese populations. However, our findings need to be validated by additional population-based prospective studies with different ethnic groups and well-designed clinical investigations. For future association studies, strict selection of patients, much larger sample size will be required. More studies should also be carried out to

examine the impact of HHEX on CRC risk, especially in different populations.

MATERIALS AND METHODS

Ethics statement

The information obtained during the study did not affect the patients' diagnosis or treatment. The protocol was approved by the Committee on Research Ethics from PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, and all subjects signed an informed consent term. Clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki.

Study population

In this study, 300 T2DM patients without secondary colorectal cancer (T2DM-only), 135 T2DM with secondary colorectal cancer patients (T2DM/CRC), 570 cancer-free controls (Control) and 642 colorectal cancer (CRC-only) cases were enrolled. All the cancer cases were histopathologically confirmed to be colorectal cancer for the first time and without history of other cancer and anti-cancer therapy. The disease was classified according to World Health Organization (WHO) criteria and were staged according to the American Joint Committee on Cancer (AJCC) TNM (tumor–node–metastasis) classification. Diabetes was characterized by persistent hyperglycaemia and was diagnosed by criteria defined in the 'Diagnosis and classification of diabetes mellitus' (American Diabetes Association) [43].

Clinical and anthropometric profiles and laboratory analyses

A standard questionnaire was used to collect information from all patients about age, age at T2DM diagnosis, treatment and et al. All selected patients or volunteers underwent physical and laboratory evaluations. They were weighed (barefoot and wearing light outdoor clothing) and had their height measured. Body mass index (BMI) was calculated as body weight (kg) divided by square of height (m²). Whole blood samples were collected of all the health volunteer control or at the first visit of the T2DM patients, or before the first cycle of chemotherapy of the CRC patients. The levels of fasting serum glucose, insulin and HbA1c were assessed in the Department of Clinical Laboratory of our hospital. Insulin levels were measured by electro chemiluminescence immunoassay method using ADVIA Centaur XP Immunoassay System. Glucose levels were measured by GOD-POD assay using ADVIA 2400 Chemistry System. HbA1c was measured by high-performance liquid chromatography (HPLC) by a BIO-RAD D-10™ autoanalyzer according to the manufacture's instruction.

Molecular analysis

DNA was extracted from peripheral blood leukocytes by a standardized salting-out procedure. Double-stranded direct sequencing was used to detect the selected SNPs of all the samples. Direct sequencing in an automated ABI 3100 Avant Genetic Analyzer (Life Technologies, Foster City, CA, USA) was performed using ABI Prism Big Dye Terminator Cycle Sequence Ready reaction kit (Life Technologies) according to the manufacturers' recommendations, and using primers described in Table S3. The results generated by sequencing were compared with the sequences of the human gene sequence available in GenBank (<http://www.ncbi.nlm.nih.gov/genbank/>). The representative sequencing results of the three genotypes of rs1111875 and rs7923837 were described in Figure S1 and Figure S2.

Statistical analyses

Statistical analysis was performed with SPSS version 13.0 (SPSS Institute, Chicago, IL). The χ^2 test was used to compare categorical data including gender, SNP cases, et al. Two sided $P < 0.05$ was considered as statistically significant. Allelic frequencies were determined by gene counting, and departures from the Hardy-Weinberg equilibrium (HWE) were investigated using chi-squared test and $P < 0.05$ indicated deviation from the equilibrium.

Abbreviations

CRC: colorectal cancer; DM: Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; HHEX: hematopoietically-expressed homeobox; T2DM-only: T2DM patients without secondary colorectal cancer; T2DM/CRC: T2DM patients with secondary colorectal cancer; CRC-only: CRC patients without the DM history.

ACKNOWLEDGMENTS

This work was supported by National Natural Science Foundation of China (No. 81502461), and Natural Science Foundation of Hubei province (2012FFB05601). We thank Prof. Yan-Li (Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, People's Republic of China) for discussion and helpful comments.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. *J Natl Cancer Inst.* 2005; 97: 1679-1687.
2. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. *Int J Cancer.* 2007; 121: 856-862.
3. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. *Diabetologia.* 2007; 50: 1365-1374.
4. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. *BMC Cancer.* 2013; 13: 310.
5. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol.* 2006; 4: 369-380.
6. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. *Eur J Cancer.* 2011; 47: 1928-1937.
7. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. *JAMA.* 2008; 300: 2754-2764.
8. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. *Acta Diabetol.* 2010; 47: 87-95.
9. Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer. *Diabetes Metab J.* 2011; 35: 193-198.
10. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning. *Science.* 2005; 307: 370-373.
11. Rich SS. Mapping genes in diabetes. Genetic epidemiological perspective. *Diabetes.* 1990; 39: 1315-1319.
12. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, Negri E, Straif K, Romieu I, La Vecchia C, Boffetta P, Jenab M. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol.* 2011; 22: 1958-1972.
13. Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Norat T. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. *PLoS One.* 2011; 6: e20456.
14. Gong J, Hutter C, Baron JA, Berndt S, Caan B, Campbell PT, Casey G, Chan AT, Cotterchio M, Fuchs CS, Gallinger S, Giovannucci E, Harrison T, et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. *Cancer Epidemiol Biomarkers Prev.* 2012; 21: 1974-1985.
15. Renehan AG, Flood A, Adams KF, Olden M, Hollenbeck AR, Cross AJ, Leitzmann MF. Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. *Am J Epidemiol.* 2012; 176: 1130-1140.
16. Yang IP, Tsai HL, Huang CW, Lu CY, Miao ZF, Chang SF, Hank Juo SH, Wang JY. High blood sugar levels

- significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2. *Oncotarget*. 2016; doi: 10.18632/oncotarget.7719.
17. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell*. 2007; 12: 9-22.
 18. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. *Mol Endocrinol*. 2010; 24: 1441-1452.
 19. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. *Endocr Relat Cancer*. 2012; 19: F27-45.
 20. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature*. 2007; 445: 881-885.
 21. Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altmuler D, Almgren P, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science*. 2007; 316: 1331-1336.
 22. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, et al. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. *Diabetes*. 2009; 58: 1690-1699.
 23. Takeuchi, F., Serizawa, M., Yamamoto, K., Fujisawa, T., Nakashima, E., Ohnaka, K., Ikegami, H., Sugiyama, T., Katsuya, T., Miyagishi, M., Nakashima, N., Nawata, H., Nakamura, J., Kono, S., Takayanagi, R., Kato, N. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. *Diabetes*. 2009; 58:1690-1699.
 24. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet*. 2010; 42: 579-589.
 25. Shu XO, Long J, Cai Q, Qi L, Xiang YB, Cho YS, Tai ES, Li X., Lin X, Chow WH, Go MJ, Seielstad M, Bao W, Li H, et al. Identification of new genetic risk variants for type 2 diabetes. *PLoS Genet*. 2010; 6: e1001127.
 26. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. *Oncotarget*. 2010; 1: 552-566. doi: 10.18632/oncotarget.191.
 27. Foley AC, Mercola M. Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. *Genes Dev*. 2005; 19: 387-396.
 28. Hunter MP, Wilson CM, Jiang X, Cong R, Vasavada H, Kaestner KH, Bogue CW. The homeobox gene Hhex is essential for proper hepatoblast differentiation and bile duct morphogenesis. *Dev Biol*. 2007; 308: 355-367.
 29. Liu C, Zhang Y, Li J, Wang Y, Ren F, Zhou Y, Wu Y, Feng Y, Zhou Y, Su F, Jia B, Wang D, Chang Z. p15RS/RPRD1A (p15INK4b-related sequence/regulation of nuclear pre-mRNA domain-containing protein 1A) interacts with HDAC2 in inhibition of the Wnt/beta-catenin signaling pathway. *J Biol Chem*. 2015; 290: 9701-9713.
 30. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proc Natl Acad Sci U S A*. 1995; 92: 3046-3050.
 31. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with beta-catenin. *Science*. 1993; 262: 1731-1734.
 32. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in *Xenopus* embryos. *Cell*. 1996. 86: 391-399.
 33. Behrens J, von KJP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. *Nature*. 1996; 382: 638-642.
 34. Cook D, Fry MJ, Hughes K, Sumathipala R, Woodgett JR, Dale TC, et al. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. *EMBO J*. 1996; 15: 4526-4536.
 35. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. *Cell*. 2000; 103: 311-320.
 36. Korinek V, Barker N, Morin PJ, van Wichen D de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. *Science*. 1997; 275: 1784-1787.
 37. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science*. 1997; 275: 1787-1790.
 38. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, Weedon MN, Mari A, Hattersley A.T., McCarthy M.I., Frayling T.M., Walker M. Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. *Diabetes*. 2007; 56: 3101-3104.
 39. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A, Clausen JO, Rasmussen SS, Jorgensen T, Sandbaek A, Lauritzen T, Schmitz O, Hansen T, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects:

- validation and extension of genome-wide association studies. *Diabetes*. 2007; 56: 3105-3111.
40. Staiger H, Stancakova A, Zilinskaite J, Vanttinen M, Hansen T, Marini MA, Hammarstedt A, Jansson PA, Sesti G, Smith U, Pedersen O, Laakso M, Stefan N, et al. A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. *Diabetes*. 2008; 57: 514-517.
 41. Pivovarova O, Nikiforova VJ, Pfeiffer AF, Rudovich N. The influence of genetic variations in HHEX gene on insulin metabolism in the German MESYBEPO cohort. *Diabetes Metab Res Rev*. 2009; 25: 156-162.
 42. Weireter LJ Jr, Collins JN, Britt RC, Novosel T.J., Britt L.D. Withdrawal of care in a trauma intensive care unit: the impact on mortality rate. *Am Surg*. 2014; 80: 764-767.
 43. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2014; 37: S81-90.
 44. Sun L, Yu S. Diabetes mellitus is an independent risk factor for colorectal cancer. *Dig Dis Sci*. 2012; 57: 1586-1597.
 45. Vu HT, Ufere N, Yan Y, Wang JS, Early DS, Elwing JE. Diabetes mellitus increases risk for colorectal adenomas in younger patients. *World J Gastroenterol*. 2014; 20: 6946-6952.
 46. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. *Am J Clin Nutr*. 2007; 86: s836-842.
 47. Berster JM, Goke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. *Arch Physiol Biochem*. 2008; 114: 84-98.
 48. Aleksandrova K, Boeing H, Jenab M, Bas Bueno-de-Mesquita H, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Overvad K, Østergaard JN, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. *Cancer Prev Res (Phila)*. 2011; 4: 1873-1883.
 49. Giouleme O, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. *World J Gastroenterol*. 2011; 17: 444-448.
 50. Marfil V, Blazquez M, Serrano F, Castell JV, Bort R. Growth-promoting and tumorigenic activity of c-Myc is suppressed by Hhex. *Oncogene*. 2015; 34:3011-3022.
 51. Ma RC, So WY, Tam CH, Luk AO, Ho JS, Wang Y, Lam VK, Lee HM, Kong AP, Tong PC, Xu G, Chow CC, Ng MC, et al. Genetic variants for type 2 diabetes and new-onset cancer in Chinese with type 2 diabetes. *Diabetes Res Clin Pract*. 2014; 103:328-337.